Efficacy of hydroxychloroquine in graves disease in addition to antithyroid drugs.
Phase 3
- Conditions
- Health Condition 1: E050- Thyrotoxicosis with diffuse goiter
- Registration Number
- CTRI/2023/07/054894
- Lead Sponsor
- IPQA laboratories
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with newly diagnosed Graveâ??s disease with serum total T4 levels more than 20 microgram/dl.
Exclusion Criteria
1. Pregnant and lactating women
2. Patients on corticosteroids or immunosuppressive drugs
3. Patients in whom the use of hydroxychloroquine is contraindicated.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Remission of Graves disease asymptomatic with normalization of TFT & negative anti TSH receptor antibodies <br/ ><br>Time required for normalization of TFTTimepoint: 1 year
- Secondary Outcome Measures
Name Time Method Reduction in clinical activity score in Graveâ??s disease patients with ophthalmopathyTimepoint: 1 year